Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Inovio Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:INO | Benzinga
Inovio Pharmaceuticals Inc has a consensus price target of $14.88 based on the ratings of 9 analysts. The high is $40 issued by Oppenheimer on March 8, 2024. The low is $2 issued by B of A Securities on November 1, 2022. The 3 most-recent analyst ratings were released by RBC Capital, Oppenheimer, and RBC Capital on May 14, 2025, May 14, 2025, and March 19, 2025, respectively. With an average price target of $7.67 between RBC Capital, Oppenheimer, and RBC Capital, there's an implied 285.26% upside for Inovio Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
Oppenheimer
HC Wainwright & Co.
Citizens Capital Markets
JMP Securities
1calculated from analyst ratings
Analyst Ratings for Inovio Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/14/2025 | Buy Now | 151.26% | RBC Capital | Gregory Renza48% | $5 → $5 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 05/14/2025 | Buy Now | 553.27% | Oppenheimer | Jay Olson60% | $15 → $13 | Maintains | Outperform | Get Alert |
| 03/19/2025 | Buy Now | 151.26% | RBC Capital | Gregory Renza48% | $6 → $5 | Maintains | Sector Perform | Get Alert |
| 03/19/2025 | Buy Now | 50.75% | HC Wainwright & Co. | Raghuram Selvaraju42% | $3 → $3 | Reiterates | Neutral → Neutral | Get Alert |
| 03/14/2025 | Buy Now | 804.52% | Citizens Capital Markets | Roy Buchanan38% | $18 → $18 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 01/13/2025 | Buy Now | 50.75% | HC Wainwright & Co. | Raghuram Selvaraju42% | $5 → $3 | Maintains | Neutral | Get Alert |
| 01/10/2025 | Buy Now | 804.52% | JMP Securities | Roy Buchanan38% | $18 → $18 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/18/2024 | Buy Now | 151.26% | HC Wainwright & Co. | Raghuram Selvaraju42% | $12 → $5 | Maintains | Neutral | Get Alert |
| 11/18/2024 | Buy Now | 653.77% | Oppenheimer | Jay Olson60% | $33 → $15 | Maintains | Outperform | Get Alert |
| 11/15/2024 | Buy Now | 201.51% | RBC Capital | Gregory Renza48% | $7 → $6 | Maintains | Sector Perform | Get Alert |
| 10/04/2024 | Buy Now | 251.76% | RBC Capital | Gregory Renza48% | $8 → $7 | Maintains | Sector Perform | Get Alert |
| 08/12/2024 | Buy Now | 1558.29% | Oppenheimer | Jay Olson60% | $40 → $33 | Maintains | Outperform | Get Alert |
| 08/09/2024 | Buy Now | 302.01% | RBC Capital | Gregory Renza48% | $11 → $8 | Maintains | Sector Perform | Get Alert |
| 07/15/2024 | Buy Now | 653.77% | HC Wainwright & Co. | Raghuram Selvaraju42% | $15 → $15 | Reiterates | Neutral → Neutral | Get Alert |
| 05/14/2024 | Buy Now | 905.03% | Stephens & Co. | Sudan Loganathan32% | → $20 | Initiates | → Overweight | Get Alert |
| 03/08/2024 | Buy Now | 1910.05% | Oppenheimer | Hartaj Singh45% | $40 → $40 | Maintains | Outperform | Get Alert |
| 03/07/2024 | Buy Now | 452.76% | RBC Capital | Gregory Renza48% | → $11 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 01/25/2024 | Buy Now | 101.01% | Oppenheimer | Hartaj Singh45% | → $4 | Upgrade | Perform → Outperform | Get Alert |
| 01/04/2024 | Buy Now | -49.75% | JMP Securities | Roy Buchanan38% | → $1 | Initiates | → Market Outperform | Get Alert |
| 05/11/2023 | Buy Now | 0.5% | RBC Capital | Gregory Renza48% | → $2 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 03/02/2023 | Buy Now | 0.5% | RBC Capital | Gregory Renza48% | $3 → $2 | Maintains | Sector Perform | Get Alert |
| 11/09/2022 | Buy Now | — | Maxim Group | Jason McCarthy42% | — | Downgrade | Buy → Hold | Get Alert |
| 11/01/2022 | Buy Now | 0.5% | B of A Securities | Geoff Meacham60% | → $2 | Downgrade | Neutral → Underperform | Get Alert |
| 08/10/2022 | Buy Now | 50.75% | RBC Capital | Gregory Renza48% | $4 → $3 | Maintains | Sector Perform | Get Alert |
FAQ
What is the target price for Inovio Pharmaceuticals (INO) stock?
The latest price target for Inovio Pharmaceuticals (NASDAQ:INO) was reported by RBC Capital on May 14, 2025. The analyst firm set a price target for $5.00 expecting INO to rise to within 12 months (a possible 133.69% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Inovio Pharmaceuticals (INO)?
The latest analyst rating for Inovio Pharmaceuticals (NASDAQ:INO) was provided by RBC Capital, and Inovio Pharmaceuticals reiterated their sector perform rating.
When was the last upgrade for Inovio Pharmaceuticals (INO)?
The last upgrade for Inovio Pharmaceuticals Inc happened on January 25, 2024 when Oppenheimer raised their price target to $4. Oppenheimer previously had a perform for Inovio Pharmaceuticals Inc.
When was the last downgrade for Inovio Pharmaceuticals (INO)?
The last downgrade for Inovio Pharmaceuticals Inc happened on November 9, 2022 when Maxim Group changed their price target from N/A to N/A for Inovio Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Inovio Pharmaceuticals (INO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Inovio Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Inovio Pharmaceuticals was filed on May 14, 2025 so you should expect the next rating to be made available sometime around May 14, 2026.
Is the Analyst Rating Inovio Pharmaceuticals (INO) correct?
While ratings are subjective and will change, the latest Inovio Pharmaceuticals (INO) rating was a reiterated with a price target of $5.00 to $5.00. The current price Inovio Pharmaceuticals (INO) is trading at is $2.14, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
